GHRL and breast carcinoma: These results support and extend previous data from our group showing that In1-ghrelin influences key, clinically relevant processes, such as proliferation or hormone secretion in other endocrine-related pathologies as breast cancer [15] and pituitary adenomas [21], further suggesting that overexpression of In1-ghrelin might be a common cellular/molecular signature across different endocrine-related tumors that is directly associated to the aggressive features of these pathologies.